source
- TriGemX Bio to go public via SPAC to advance migraine drug candidateTriGemX Bio, formerly known as Kallyope, said it will become a public company by merging with a special purpose acquisition company. The transaction is aimed at raising capital and accelerating the…
- Enlivex cuts 60% of staff, halts preclinical R&D and slashes exec salaries to fund osteoarthritis trialEnlivex, an Israeli biotech developing a cell‑based immunotherapy called allocetra for knee osteoarthritis, announced today that it is reducing its workforce by 60 percent. The cut reduces the sta…